Develops and sells protein-based vaccines, including a COVID-19 vaccine and a combination flu/COVID pipeline.
Develops and sells protein-based vaccines, including a COVID-19 vaccine and a combination flu/COVID pipeline.
Under a 2024 deal Sanofi now sells the COVID shot in most markets, so Novavax earns mainly milestone payments and royalties rather than its own product sales. Its Matrix-M adjuvant, an ingredient that strengthens the immune response, is also licensed into other makers' vaccines, including the R21 malaria vaccine. The company has cut costs sharply to match.
Moat: narrow (IP / patents, regulatory licence). Proprietary Matrix-M adjuvant and protein-vaccine platform, but a distant also-ran versus mRNA COVID vaccine leaders.
Headquarters: Gaithersburg, Maryland, US · Founded: 1987 · Employees: 749
Size Novavax (NVAX) is a United States Health Care company (Biotechnology) with a market value of $1.31B, the 2057th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.96 on 18 Nov 2026.
Performance Over six months the shares fell 14.1%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue fell 61.3% over the last twelve months (peer median +15.8%); the operating margin is -16.5% (peer median -178.1%).
Valuation It trades at 134.6× forward earnings against a peer median of 38.6× (2nd most expensive of 8).
Short interest Short interest is 28.1% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $412M | $1.12B | $682M | $984M | $1.98B |
| Revenue growth | — | +65% | -31% | -50% | — |
| Gross profit | $323M | $1.05B | $484M | $704M | $1.08B |
| EBITDA | -$53.7M | $591M | -$183M | -$374M | -$616M |
| Net income | -$76.7M | $440M | -$187M | -$545M | -$658M |
| Free cash flow | -$244M | -$250M | -$100M | -$771M | -$505M |
| Capital expenditure | $4.96M | $6.39M | $14.6M | $58.8M | $93.0M |
| Total debt | $295M | $278M | $263M | $281M | $617M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Novavax NVAX | $1.31B | -14% | -61% | -17% | 134.6× | n/a |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| Moderna MRNA | $79.6B | +309% | +13% | -116% | n/a | n/a |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
| GSK GSK.L | $97.9B | -3% | +4% | 25% | 10.4× | -0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NVAX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -30.4% | -15.2% | 2nd lowest of 21 |
| 6-month return | -14.1% | -20.3% | 7th highest of 20 |
| Distance from 52-week high | -40.5% | -48.1% | 8th highest of 21 |
| Revenue growth (TTM) | -61.3% | +15.8% | lowest of 18 |
| Operating margin | -16.5% | -178.1% | 9th highest of 19 |
| Forward P/E | 134.6× | 38.6× | 2nd most expensive of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 134.6× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | n/a | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.36B | -23% | +36% | -4% | 60.5× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | n/a | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | n/a | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 38.6× | 33.2% | -13.1% |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.24B | -21% | +1% | 10% | 26.5× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 4.9× | 0.5% | +25.6% |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.22B | -14% | -9% | 0% | 44.0× | 6.6% | -7.0% |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | n/a | n/a | n/a |
| Mineralys Therapeutics MLYS | United States | $1.22B | -52% | n/a | n/a | n/a | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | n/a | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 137.8× | 39.4% | -2.5% |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.21B | +38% | +18% | 10% | 25.6× | 15.3% | +9.9% |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | n/a | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | n/a | n/a | n/a |